November 22, 2024 22:34 (IST)
CCI approves merger of Serum Institute subsidiaries Biocon Biologics and CTPL
New Delhi: The Competition Commission of India (CCI) has approved the merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for the acquisition of approximately 15 percent equity shareholding of Biocon Biologics by Serum Institute Life Sciences.
Boris Johnson announces Serum Institute of India to invest 240 million pounds in UK
London: British PM Boris Johnson has announced the Serum Institute of India (SII), the manufacturers of COVID-19 vaccine Covishield, will be investing 240 million pounds in the United Kingdom through the opening of a new sales office, media reports said.
Latest Headlines